Published Online: August
03, 2015
Recognition of differing
risks of locoregional recurrence (LRR) in breast cancer patients based on
estrogen receptor, progesterone receptor, and HER2 status, coupled with a
reduction in LRR in patients receiving adjuvant systemic therapy, offers the
opportunity to tailor surgical treatment and reduce the morbidity of therapy.
New guidelines for margins in breast-conserving therapy of tumor not touching
ink and avoidance of axillary dissection in sentinel node positive patients
undergoing breast-conserving therapy are examples of this approach which have
entered practice.
